Inpharmatica Ltd's GPCR SARfari is a comprehensive and easily accessible knowledge-base covering a group of receptors widely exploited in drug discovery. More than 40percent of the drugs on the market today target these receptors and generate annual sales in excess of USbillion.
GPCR SARfari covers many of the most important G protein-coupled receptors (GPCRs). It contains the relevant chemical, natural ligand, structural and biological information on all 297 human rhodopsin-like (non-olfactory) GPCRs.
Inpharmatica has designed GPCR SARfari to provide both biologists and chemists working in this important area with a single essential data resource. It includes protein sequences, proprietary 3D-structures, corresponding natural ligands and over 60000 drug-like compounds derived from StARLITe (Inpharmatica's proprietary database of medical chemistry and pharmacology). This web-accessible resource is fully searchable by compound, protein sequence and text.
Structured for ease of use, it will considerably enhance in-house knowledge to progress GPCR drug discovery programmes.
GPCR SARfari is a component of PharmaCarta, Inpharmatica's gene-to-candidate technology platform that integrates biology- and chemistry-based drug discovery activities.
PharmaCarta optimises target selection based on druggability, enables rapid identification of hits and selection of high quality leads and pre-clinical candidates, which are prioritised on the basis of good drug-like characteristics.
John Lisle, CEO of Inpharmatica, said: “We have used our expertise in protein modelling and database building to deliver a product for desk tops that not only incorporates all we have learned in modelling and GPCR ligand binding, but which also addresses key questions in GPCR focused pharmaceutical research.“
Inpharmatica Ltd is a selective drug discovery company using predictive technologies to improve speed and productivity. Focusing on highly druggable targets, its proprietary platform, PharmaCarta, is an integrated suite of informatics-based technologies fully capable of rapid gene to candidate operations.
The company's lead discovery programmes are focused on generating pre-clinical candidates against a number of precedented and novel nuclear receptors proteins widely considered to be both druggable and of high therapeutic interest.
For more information, visit www.inpharmatica.com
